Opioid use disorder is treatable, and the research on what works is no longer ambiguous. A well-structured MAT program for opioid addiction in Southern Indiana combines FDA-approved medication with clinical counseling, and the evidence behind that combination is strong enough that choosing a provider without understanding how these elements fit together is one of the most consequential mistakes you can make.
What MAT actually does (and why it works)
A 2021 SAMHSA analysis of over 40 years of clinical data found that medication-assisted treatment reduces opioid use, lowers overdose mortality, and improves treatment retention compared to abstinence-only approaches. The mechanism is straightforward: opioid use disorder involves physical changes in the brain’s reward and stress systems. Medication stabilizes those systems while counseling addresses the behavioral patterns and underlying conditions that drove the addiction in the first place.
What MAT is not: a substitute addiction or a shortcut. That framing, still common in some communities, has been rejected by every major medical authority including SAMHSA, NIDA, and the American Society of Addiction Medicine. MAT is a medical treatment with a strong evidence base, and withholding it would be comparable to withholding insulin from a diabetic patient because the medication is “just replacing one substance with another.”
The action here is specific: look up the DSM-5 clinical criteria for opioid use disorder. If you or a family member meets two or more of those criteria, MAT is a clinically appropriate option worth discussing with a prescriber.
The three FDA-approved medications explained
A 2022 NIDA review comparing outcomes across all three FDA-approved MAT medications found that buprenorphine and methadone produced comparable reductions in illicit opioid use, while naltrexone showed strong results specifically in patients who had already completed detoxification.
Buprenorphine, most commonly prescribed as Suboxone (a sublingual film combining buprenorphine with naloxone), works as a partial opioid agonist. It reduces cravings and withdrawal symptoms without producing the full euphoric effect of opioids. It is typically prescribed in an outpatient setting and taken daily at home. Methadone is a full agonist, dispensed daily through federally certified opioid treatment programs, and is generally reserved for individuals with severe or long-term dependence. Naltrexone, available as a monthly injectable called Vivitrol, is an opioid antagonist: it blocks opioid receptors entirely and produces no opioid effect. It is well-suited for patients who have completed medically supervised withdrawal and want a non-opioid option. For a closer look at whether the injectable format fits your situation, understanding the trade-offs of the monthly injection is worth reviewing before your first prescriber conversation.
Ask a prescriber which medication aligns with your specific use history, the severity of your dependence, and your insurance coverage. That conversation should happen at or before your first intake appointment.
Counseling as a required component, not an add-on
A 2021 analysis published in the Journal of Substance Abuse Treatment followed 1,200 patients across multiple MAT programs and found that patients receiving structured behavioral counseling alongside medication had significantly higher 12-month retention rates and lower relapse rates than those receiving medication alone.
In practice, outpatient counseling within a MAT program includes individual therapy sessions, group programming, and in many cases structured family involvement. The counseling component addresses the triggers, thought patterns, and co-occurring mental health conditions that medication alone cannot reach. When evaluating any MAT program, confirm that counseling is structured and required, not listed as optional or left to the patient to arrange independently.
What to look for in a southern indiana MAT program
Not all MAT programs in Clark County and the Greater Louisville metro are built the same way. A 2022 IQVIA report on Indiana’s opioid treatment capacity found significant variation in access, staffing ratios, and payer acceptance across the state, with rural and semi-rural counties consistently showing longer wait times and fewer integrated service options. The criteria below separate a program that produces outcomes from one that processes paperwork.
Medication access without excessive barriers
A 2023 Health Affairs analysis found that each additional week of delay between a patient’s first contact with a treatment provider and their first MAT prescription increased dropout risk by 12%. Waitlists and excessive prior authorization requirements are not administrative inconveniences; they are clinical risks.
Before committing to a program, call and ask three specific questions: How quickly can an intake appointment be scheduled? Is buprenorphine prescribed at the first visit if it is clinically appropriate? Are telehealth options available for ongoing follow-up so that missing one appointment does not interrupt your medication? For a detailed breakdown of what the intake process looks like in Clark County specifically, what to expect from local treatment options covers the practical steps.
Insurance coverage and payer acceptance
A 2023 KFF report on Medicaid coverage of substance use disorder treatment found that cost remains one of the top three barriers to MAT access nationally, even among insured patients, largely because in-network status and prior authorization requirements vary by medication and plan.
Southern Indiana residents have a broad payer landscape to navigate. Commercial plans including Anthem BCBS, Cigna, and Optum each have different prior authorization requirements for buprenorphine versus Vivitrol. Tricare has its own approval pathway. Indiana Medicaid plans, including Anthem, CareSource, MDwise, and Optum, generally cover MAT medications but may require step therapy documentation. Before your first appointment, contact your insurer directly and ask whether your prospective MAT provider is in-network and whether the specific medication being considered requires prior authorization under your plan.
Co-occurring mental health treatment
The 2021 National Survey on Drug Use and Health found that more than 50% of adults with opioid use disorder also meet criteria for at least one co-occurring mental health condition, most commonly depression, anxiety, or PTSD. Treating the addiction without addressing the underlying condition produces higher relapse rates, and programs that require a separate referral for mental health care introduce gaps that patients frequently fall through.
Look for programs with integrated behavioral health, meaning psychiatric evaluation and mental health treatment happen on-site within the same clinical team rather than requiring a separate provider. Ask any prospective program directly: does psychiatric care happen here, or will you refer me out?
Common mistakes when choosing a MAT program
Stopping medication too early
A 2022 JAMA Psychiatry study of 40,000 patients on buprenorphine found that discontinuing the medication within the first 12 months was associated with a three-fold increase in overdose risk in the 30 days following discontinuation. The brain’s opioid receptors require sustained stabilization, and “feeling better” is not a reliable clinical signal that the medication is no longer needed. In fact, feeling better is often the direct result of the medication working correctly.
At your first appointment, ask your prescriber for a specific minimum treatment timeline, not a vague answer. A number like 12 to 24 months gives you a target to plan around and helps you resist the pressure, whether internal or external, to taper prematurely.
Other consequential mistakes include selecting a program based on proximity alone without verifying payer acceptance, and choosing a provider that does not address co-occurring mental health conditions. If you are evaluating Suboxone providers in the area, payer verification and the presence of integrated mental health services are the two non-negotiable questions to answer before signing intake paperwork.
Questions to ask before enrolling in a MAT program
SAMHSA’s Treatment Improvement Protocol 63 identifies several structural markers of quality in outpatient substance use programs. Use these as your filter when making calls or visiting programs.
Ask about prescriber credentials and DEA registration for controlled substances. Since the 2023 Omnibus eliminated the separate DATA waiver requirement, any DEA-registered clinician can prescribe buprenorphine, but you still want to know whether the prescriber has specific addiction medicine training. Ask what medications are offered: a program that only offers one option may not be matching medication to patient need.
Ask how counseling is structured: how often, in what format, and whether attendance is tracked and required. Ask whether telehealth is available for follow-up appointments when transportation or scheduling is a barrier. Ask what happens if you relapse: a quality program treats relapse as a clinical event requiring adjusted care, not grounds for discharge. Ask whether crisis support is accessible between scheduled appointments.
Programs that resist answering these questions directly are communicating something about how they operate. Resistance to transparency is itself a data point.
Starting MAT in southern indiana this week
A 2023 CDC report on opioid overdose mortality found that each month of delay between initial help-seeking and treatment entry is associated with measurably worse outcomes, both in terms of continued overdose risk and long-term recovery rates. The research on timing is not ambiguous: earlier entry produces better results.
The one action to take this week: contact a local outpatient MAT provider, confirm your insurance coverage and in-network status, and request an intake appointment. Do not wait until the timing feels perfect. The timing will not feel perfect. What changes the outcome is making the call.
Frequently asked questions
How long does MAT for opioid addiction typically last?
The research is clear that duration matters. A 2022 JAMA Psychiatry study found that discontinuing buprenorphine within 12 months significantly increases overdose risk. Most clinical guidelines recommend a minimum of 12 to 24 months, with duration ultimately determined by your prescriber based on stability, mental health status, and life circumstances. There is no universal endpoint, and the decision to taper should be made with your clinical team, not based on how you feel in the short term.
Does insurance cover MAT in indiana?
Most major commercial plans and all Indiana Medicaid plans cover FDA-approved MAT medications, but coverage details vary by plan and medication. Anthem BCBS, Cigna, Optum, CareSource, and MDwise all cover buprenorphine and naltrexone under their Indiana formularies, though some plans require prior authorization. Tricare covers MAT with its own approval process. Call your insurer before your first appointment and ask specifically about in-network status and prior authorization requirements for the medication being considered.
Can MAT be done entirely on an outpatient basis?
Yes. Buprenorphine and naltrexone (Vivitrol) are both prescribed in outpatient settings. Methadone requires daily dispensing at a federally certified opioid treatment program, but buprenorphine and Vivitrol can be managed through outpatient appointments with telehealth follow-up available in many programs. Outpatient MAT allows you to maintain work, family, and daily responsibilities while in treatment.
What is the difference between suboxone and vivitrol?
Suboxone is a buprenorphine/naloxone film taken daily under the tongue. It is a partial opioid agonist, meaning it reduces cravings and withdrawal by partially activating opioid receptors. Vivitrol is a monthly naltrexone injection that blocks opioid receptors entirely and produces no opioid effect. Suboxone is typically appropriate for patients who are physically dependent and have not yet completed detoxification. Vivitrol requires that the patient be fully opioid-free before the first injection, or it will precipitate withdrawal.
What happens if I relapse while on MAT?
Relapse during treatment is a clinical event, not a moral failure, and a quality program treats it that way. In a well-structured outpatient MAT program, relapse triggers a clinical reassessment: the care team reviews what happened, adjusts the treatment plan as needed, and continues medication. Programs that discharge patients for relapsing are not following evidence-based care standards. Ask any prospective program directly how they handle relapse before you enroll.
Do I need a referral to start MAT in southern indiana?
No referral is required. Most outpatient MAT programs in the Jeffersonville and Clark County area accept self-referrals. You can call directly, confirm your insurance, and request an intake appointment. Family members can also initiate the contact on behalf of a loved one if the individual is not yet ready to make the call themselves.
